Skip to main content

Catalys Pacific Strengthens Company Creation Team with New Operating Partner December 9, 2019

Tokyo, Japan – December 9, 2019

Catalys Pacific announced Hito (Hidehito) Kotani has joined the team at Catalys Pacific as Operating Partner.  He will focus on creating new life sciences venture companies and leading the portfolio companies for growth and further development.

Hito is an expert in regional development of global products for Japan and Asia, bringing over 20 years of experience in basic and clinical R&D, regulatory science, and strategy / business development / sales & marketing in Japan and Asia at multiple global pharma including Pfizer and Merck.

From 2015 through 2019, Hito worked as President, CEO and CTO of PHC Holdings Corporation (formerly known as Panasonic Healthcare Holdings Co., Ltd.).  Prior to PHC, from 1998 to 2015, he served as Chair of global clinical development, led the groups of functional genomics and bioinformatics, and served as global head of oncology at MSD K.K. (a wholly owned subsidiary of Merck & Co., Inc.).  Thereafter, he served as Executive Vice President where he was responsible for regional strategy and business development & licensing at MSD K.K.  From 1994 to 1998, he was a research fellow at Pfizer Central Research in Connecticut.

Dr. Kotani trained at Whitehead Institute at Massachusetts Institute of Technology and received his Ph.D. in Molecular Medicine & Genetics at Thomas Jefferson University.

“We are delighted to have Hito join our team.  We believe his skills and experience will enable us to strengthen our capabilities and efforts to transform life sciences innovation in Japan through the creation of and investment in global companies in Japan,” said BT Slingsby, Founder & Managing Partner of Catalys Pacific.

“I am excited to partner with Catalys Pacific to drive forward life sciences innovation with Japan.  There are still many unmet medical needs for patients in Japan, Asia, and the rest of the world.  Together, we must be the ones to deliver bright futures for patients,” said Hito.

About Catalys Pacific

Catalys Pacific is an independent venture capital firm focusing on early-stage investments in life sciences.  Founded in 2019, the firm’s mission is to focus on providing healthcare solutions for patients worldwide through the creation of and investment in bioventure companies.  Catalys Pacific is led by a global team versed in working closely with its partners in academia, biotech, venture capital and the pharmaceutical industry in Japan and worldwide.  The firm maintains offices in Tokyo and Kanagawa (Shonan Health Innovation Park), Japan and in San Francisco, California.

Please see https://catalyspacific.com for more information.